Article
Psychiatry
Giuseppe Cicala, Renato de Filippis, Maria Antonietta Barbieri, Paola Maria Cutroneo, Pasquale De Fazio, Georgios Schoretsanitis, Edoardo Spina
Summary: This study retrospectively analyzed pharmacovigilance data on Paliperidone palmitate (PP) and found that its safety and tolerability profiles are similar to other second-generation long-acting injectable antipsychotics (SGA-LAIs). However, there were some differences in adverse drug reactions related to the endocrine system. These results do not discourage the use of SGA-LAI formulations but aim to enhance their safety.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Medicine, Research & Experimental
Akitoyo Hishimoto, Norio Yasui-Furukori, Daisuke Sekine, Miyuki Matsukawa, Sakiko Yamada
Summary: This study compared the time to treatment discontinuation between patients with schizophrenia prescribed brexpiprazole (BRX) and those prescribed other atypical antipsychotics (OAA) using health insurance claims data. The results showed that patients in the BRX group were less likely to discontinue treatment and had higher treatment continuation rates compared to the OAA group.
ADVANCES IN THERAPY
(2022)
Article
Clinical Neurology
Shimeng Dong, Johannes Schneider-Thoma, Irene Bighelli, Spyridon Siafis, Dongfang Wang, Angelika Burschinski, Kristina Schestag, Myrto Samara, Stefan Leucht
Summary: In this network meta-analysis, the efficacy and adverse events of different antipsychotics in treatment-resistant schizophrenia were examined. The results showed that clozapine and olanzapine were more effective in relieving symptoms compared to other drugs. Clozapine remains the gold standard for patients with treatment-resistant schizophrenia, while olanzapine can be considered as an alternative option.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
(2023)
Review
Pharmacology & Pharmacy
Gia Han Le, Emily S. Gillissie, Taeho Greg Rhee, Bing Cao, Yazen Alnefeesi, Ziji Guo, Joshua D. Di Vincenzo, Muhammad Youshay Jawad, Andrew M. March, Ranuk Ramachandra, Leanna M. W. Lui, Roger S. McIntyre
Summary: Schizophrenia is a mental illness that can disrupt emotions, perceptions, and cognition and reduce quality of life. Evidence suggests that ulotaront, a TAAR1 agonist, may be a potential alternative treatment for schizophrenia.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Psychiatry
Larry Alphs, Brianne Brown, Ibrahim Turkoz, Pamela Baker, Dong-Jing Fu, Keith H. Nuechterlein
Summary: The DREaM study compared the effectiveness of paliperidone palmitate (PP) versus oral antipsychotics (OAP) in delaying time to first treatment failure in participants with recent-onset schizophrenia or schizophreniform disorder. The study highlighted the potential benefits of initiating PP early in the course of schizophrenia.
SCHIZOPHRENIA RESEARCH
(2022)
Review
Neurosciences
Ruqin Zhou, Meng He, Jun Fan, Ruoxi Li, Yufeng Zuo, Benben Li, Guanbin Gao, Taolei Sun
Summary: Schizophrenia and antipsychotic-induced weight gain/obesity may be associated with hypothalamic endoplasmic reticulum stress pathway, which could lead to multiple changes in the body including hyperphagia, decreased energy expenditure, and central inflammation.
FRONTIERS IN NEUROSCIENCE
(2022)
Article
Pharmacology & Pharmacy
Karina S. MacDowell, Eva Munarriz-Cuezva, J. Javier Meana, Juan C. Leza, Jorge E. Ortega
Summary: Emerging evidence suggests that early-life exposure to environmental factors may increase the risk for schizophrenia through inflammatory mechanisms. This study investigated the role of serotonergic and kynurenine pathways in the maternal immune activation (MIA) animal model of schizophrenia, and evaluated the potential reversal by long-term antipsychotic treatment.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Chemistry, Medicinal
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Valeria I. Gerasimova, Alexander N. Kornetov, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: This study compared the changes in cytokine levels in schizophrenia patients receiving atypical antipsychotics with or without metabolic syndrome. The results showed that treatment with atypical antipsychotics had different effects on inflammatory cytokine levels depending on the presence of MetS. Patients with MetS experienced increased levels of certain cytokines, while those without MetS had decreased levels of other cytokines after treatment.
Article
Clinical Neurology
Sofia Pappa, Joshua Barnett, Katy Mason
Summary: This 10-year follow-up study on the use of paliperidone palmitate once monthly (PP1M) showed that long-term treatment with PP1M can improve hospitalization rates and duration of admissions in schizophrenic and psychotic patients. The study findings suggest the potential for cost-effectiveness and facilitate shared decision making.
Article
Psychiatry
C. Wang, T. A. Tishler, K. H. Nuechterlein, B. M. Ellingson
Summary: This longitudinal study compared the effects of oral antipsychotics (OAP) and long-acting injectable antipsychotic, paliperidone palmitate (PP), on cortical thickness, gray-to-white matter contrast (GWC), and frontal lobe intracortical myelin (ICM) volume in first-episode schizophrenia (FES) patients. The results showed that OAP treatment resulted in more widespread cortical thickness reduction compared to PP treatment, suggesting that PP treatment may aid in the preservation of brain morphology.
PSYCHIATRY RESEARCH
(2023)
Review
Clinical Neurology
Stefano Bramante, Gabriele Di Salvo, Giuseppe Maina, Gianluca Rosso
Summary: International guidelines recommend long-term antipsychotic therapy for schizophrenia, but medication compliance remains a critical issue. Paliperidone palmitate is an approved second-generation antipsychotic long-acting injectable for schizophrenia treatment. This systematic review aimed to evaluate PP-LAI adherence levels and healthcare resource utilization and costs. The findings suggest that paliperidone palmitate is a good treatment strategy for schizophrenia patients, with better adherence patterns and more favorable healthcare resource utilization and costs compared to oral antipsychotics.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Review
Medicine, General & Internal
Johannes Schneider-Thoma, Konstantina Chalkou, Carola Doerries, Irene Bighelli, Anna Ceraso, Maximilian Huhn, Spyridon Siafis, John M. Davis, Andrea Cipriani, Toshi A. Furukawa, Georgia Salanti, Stefan Leucht
Summary: This study compared the efficacy and tolerability of antipsychotics as maintenance treatment for schizophrenia. The results showed that there was no clear difference between antipsychotics in terms of relapse prevention. The choice of antipsychotic for maintenance treatment should be guided mainly by their tolerability.
Article
Psychiatry
Chencai Wang, Todd A. Tishler, Talia Oughourlian, Keith H. Nuechterlein, Camilo de la Fuente-Sandoval, Benjamin M. Ellingson
Summary: Widespread anatomical alterations and abnormal functional connectivity are associated with symptom severity in FES patients. The use of long-acting injectable antipsychotics like PP may be more effective in improving cerebral organization compared to oral antipsychotics (OAP).
SCHIZOPHRENIA RESEARCH
(2023)
Article
Psychiatry
Nadia E. Crellin, Stefan Priebe, Nicola Morant, Glyn Lewis, Nick Freemantle, Sonia Johnson, Rob Horne, Vanessa Pinfold, Lyn Kent, Ruth Smith, Katherine Darton, Ruth E. Cooper, Maria Long, Jemima Thompson, Lisa Gruenwald, Robert Freudenthal, Jacki L. Stansfeld, Joanna Moncrieff
Summary: This study reveals that patients are commonly dissatisfied with the idea of taking antipsychotic medication on a long-term or life-long basis. The desire to reduce or stop medication is primarily motivated by adverse effects and health concerns. Patients value professional support in achieving reduction or discontinuation.
Review
Medicine, General & Internal
Sanjana Santhosh Kumar, Raquel Cantillo, Dongxia Ye
Summary: This review examines the oral healthcare of elderly patients with schizophrenia and emphasizes the importance of targeted dental interventions for addressing the dental health challenges faced by this vulnerable population.
JOURNAL OF CLINICAL MEDICINE
(2023)
